Introduction to Biodegradable Stents as Tissue Engineering Devices

Biodegradable stents represent a paradigm shift in vascular medicine, moving beyond permanent metallic implants toward temporary scaffolds that integrate with the body’s natural healing processes. These devices are engineered to support blood vessels immediately after interventional procedures such as angioplasty, then gradually dissolve as the vessel remodels and recovers. This approach eliminates many of the chronic complications associated with permanent stents, including late stent thrombosis, chronic inflammation, and mechanical mismatch with the native artery. As such, biodegradable stents are not merely an incremental improvement but a foundational technology in the field of vascular tissue engineering, where the ultimate goal is to restore native vascular function rather than impose a lifelong foreign body.

The concept of a stent that vanishes once its job is done has captivated researchers and clinicians for decades. Early attempts focused on polymers and bioabsorbable metals, but only in the past fifteen years have materials and manufacturing methods advanced enough to produce devices with sufficient radial strength, controlled degradation profiles, and excellent biocompatibility. Today, biodegradable stents are being tested in clinical trials for coronary artery disease, peripheral artery disease, and even pediatric vascular applications, where a growing child’s vessels cannot accommodate a permanent implant.

This article explores the design, materials, clinical evidence, and future potential of biodegradable stents as vascular tissue engineering devices. We will examine how these stents function, the advantages they offer over permanent alternatives, the challenges that remain, and the emerging technologies that promise to make them even more effective.

How Biodegradable Stents Work: Mechanism of Degradation and Tissue Integration

At their core, biodegradable stents are temporary mechanical scaffolds. After deployment via balloon catheter, they must provide enough radial force to keep the vessel open during the critical healing period, typically three to six months. Over this time, the stent gradually loses its mechanical integrity as the polymer chains hydrolyze or the metal ions corrode, transferring the mechanical load to the newly remodeled vessel wall. The degradation products—lactic acid, glycolic acid, magnesium ions, or other biocompatible byproducts—are metabolized or excreted by the body without causing systemic toxicity.

The rate of degradation is tunable by modifying polymer composition, molecular weight, crystallinity, and stent design. For example, poly(L-lactic acid) (PLLA) degrades slowly over two to three years, while polyglycolic acid (PGA) can lose strength within weeks. Magnesium alloys offer a faster degradation profile, often within six to twelve months, but require careful control to avoid local gas formation and rapid loss of support. The ideal degradation profile balances early mechanical integrity with complete resorption in a timeframe that matches arterial healing.

Tissue integration is another key aspect. As the stent degrades, the vessel wall gradually remodels around it, eventually leaving behind a fully functional, flexible artery without permanent foreign material. This process is mediated by smooth muscle cell proliferation, endothelialization, and extracellular matrix deposition. Drug-eluting coatings, often including antiproliferative agents like everolimus or sirolimus, can modulate this response to prevent excessive neointimal hyperplasia and restenosis, similar to drug-eluting permanent stents but with the added benefit of eventual removal.

Materials Used in Biodegradable Stents

The choice of material is the single most critical factor determining a biodegradable stent’s clinical performance. Materials must meet conflicting demands: they must be strong enough to resist vessel recoil yet flexible enough to navigate tortuous anatomy; they must degrade at a controlled rate without causing local inflammation; and they must be fully resorbed without leaving toxic residues. Three main classes of materials dominate the field.

Biodegradable Polymers

Polymers such as PLLA, PGA, poly(ε-caprolactone) (PCL), and their copolymers (e.g., poly(L-lactide-co-ε-caprolactone)) are the most widely studied. PLLA is the backbone of the first commercially available bioresorbable scaffold, the Abbott Vascular Absorb stent, which received CE mark approval in 2011 and FDA approval in 2016 (though later withdrawn from the market). PLLA provides high initial strength and a slow degradation profile, but its thickness (often over 150 µm) can lead to higher rates of scaffold thrombosis. Newer polymer blends aim to reduce strut thickness while maintaining mechanical integrity.

Magnesium Alloys

Magnesium-based stents, such as the Magmaris (Biotronik), offer a fully bioabsorbable metal alternative. Magnesium alloys (e.g., WE43, a magnesium-yttrium-neodymium alloy) degrade via corrosion in the body’s chloride-rich environment, producing magnesium ions that are easily excreted by the kidneys. Magnesium stents have higher radial strength than polymers, allowing thinner struts (around 100 µm), which reduces thrombosis risk. However, they degrade faster—often complete resorption within 12 months—and early-generation devices suffered from gas bubble formation. Modern alloys with protective coatings have largely solved these issues.

Iron and Zinc Alloys

Iron and zinc are being explored as alternative bioabsorbable metals. Iron degrades very slowly (years), which may be beneficial for long-term support, but its magnetic properties and potential for local toxicity raise concerns. Zinc alloys offer intermediate degradation rates and good biocompatibility, but research is still preclinical. These materials may provide a middle ground between magnesium and polymers, but clinical adoption is further away.

Advantages of Biodegradable Stents Over Permanent Implants

The clinical rationale for biodegradable stents is compelling. Permanent metallic stents, while effective, are associated with lifelong risks: late stent thrombosis, chronic inflammation leading to in-stent restenosis, neoatherosclerosis, and the inability to perform future bypass grafting at the stented site. Biodegradable stents address these limitations in several ways.

  • Restoration of Vasomotion: Once the stent degrades, the vessel regains its ability to constrict and dilate naturally. This vasomotor function is critical for maintaining normal blood flow regulation and reducing shear stress abnormalities.
  • No Permanent Foreign Body: The absence of a permanent implant eliminates the nidus for late-stage thrombosis and chronic foreign-body reaction. This is especially important in younger patients who may require multiple interventions over their lifetime.
  • Ease of Reintervention: A vanished stent means that future procedures—angioplasty, stenting, or bypass—are not complicated by the presence of a metallic scaffold. This is particularly relevant in coronary bifurcations and small vessels.
  • MRI Compatibility: Non-metallic biodegradable stents produce negligible artifact on MRI, facilitating follow-up imaging. Magnesium stents also show low MRI artifact compared to stainless steel or cobalt-chromium stents.
  • Reduced Risk of Very Late Stent Thrombosis: Permanent stents carry a small but continuous risk of thrombosis beyond one year. Biodegradable stents aim to eliminate this risk once resorption is complete.

Clinical Applications and Evidence

The most extensive clinical data for biodegradable stents come from coronary artery disease. The Absorb bioresorbable vascular scaffold (BVS) was studied in large randomized trials including the ABSORB II, III, and IV trials. Early results showed non-inferiority to metallic drug-eluting stents, but longer-term follow-up revealed higher rates of scaffold thrombosis, particularly in small vessels and with suboptimal implantation technique. This led to the withdrawal of Absorb from the market in 2017. However, subsequent analyses indicated that improvements in implantation technique—such as proper vessel sizing, high-pressure post-dilation, and avoiding underexpansion—could markedly reduce thrombosis rates.

Second-generation polymer scaffolds, using everolimus or sirolimus coatings and thinner struts (down to 100 µm), are now in clinical trials. For example, the MeRes-100 (Meril Life Sciences) and the Fantom (REVA Medical) show promising early outcomes. Magnesium-based Magmaris has been evaluated in the BIOSOLVE-II and III trials, demonstrating low rates of target lesion failure and no definite scaffold thrombosis through five years. These results suggest that biodegradable stents can achieve outcomes comparable to modern permanent stents when used in appropriate patients and with optimal technique.

Beyond coronary arteries, biodegradable stents are being investigated for peripheral applications. In the superficial femoral artery (SFA), stents face constant bending and compression; a biodegradable device that disappears after vessel healing would be ideal. Early studies of polymer and magnesium stents in the SFA show sustained patency but also highlight challenges with fracture and early recoil. Pediatric cardiovascular interventions represent another promising niche, as growing children require stents that can accommodate increasing vessel diameter; a biodegradable stent that resorbs after a few years avoids the need for repeated dilatation or surgical removal.

Challenges and Limitations

Despite their potential, biodegradable stents face significant hurdles that have slowed widespread adoption.

Mechanical Strength and Strut Thickness

Biodegradable polymers inherently have lower radial strength than permanent metals. To compensate, early stents used thicker struts (150–160 µm), which increased thrombogenicity and lesion crossing profile. Magnesium alloys offer higher strength but still degrade faster, sometimes losing support before healing is complete. Balancing these properties requires sophisticated material engineering and stent design, such as using asymmetric strut geometry or composite materials.

Degradation Control

Ensuring predictable and uniform degradation in vivo is difficult. Factors such as local pH, enzyme activity, mechanical stress, and patient comorbidities can alter degradation rates. Rapid degradation can cause luminal recoil, while slow degradation delays the benefits of resorption. Inflammatory responses to degradation products—especially fast-degrading polymers—can exacerbate restenosis.

Thrombosis Risk

First-generation biodegradable stents had higher rates of scaffold thrombosis (up to 3% at 3 years in some trials) compared to metallic drug-eluting stents. This was partly due to thick struts and inadequate anti-proliferative drug release. Newer designs with thinner struts and optimized drug-release kinetics are reducing this risk, but it remains a focus of ongoing research.

Manufacturing and Cost

Producing biodegradable stents is more complex and costly than manufacturing permanent metal stents. The need for cleanroom conditions, precise polymer processing (e.g., microinjection molding or laser cutting), and sterilization without degrading the material adds expense. Until biodegradable stents can be produced at scale and at competitive prices, their use may remain limited.

“The promise of biodegradable stents is not just that they disappear—it’s that they leave behind a healthy, functional artery. The challenge is making sure they disappear at exactly the right time.” — Dr. John A. Ormiston, interventional cardiologist and early Absorb investigator

Emerging Technologies and Future Directions

Research in biodegradable stents is accelerating, with several promising innovations on the horizon.

Drug-Eluting and Bioactive Coatings

Combining biodegradability with controlled drug release remains a key area. Next-generation stents incorporate antiproliferative drugs (e.g., sirolimus, everolimus, zotarolimus) in biodegradable polymer coatings that elute over weeks to months, then degrade. Some are exploring pro-healing coatings that attract endothelial progenitor cells to accelerate re-endothelialization, reducing thrombosis risk without strong immunosuppression.

Patient-Specific Design and 3D Printing

Advances in 3D printing and computational modeling enable patient-specific stent geometries, optimized for individual anatomy and lesion characteristics. 3D-printed biodegradable stents can have variable strut thickness, radial stiffness gradients, and even micro-pores to promote tissue ingrowth. Early preclinical results are promising, but regulatory and manufacturing hurdles remain.

Composite and Nanostructured Materials

Blending polymers with bioactive glass, hydroxyapatite, or nanoscale reinforcement fibers can improve mechanical properties and enhance tissue integration. For example, PLLA reinforced with magnesium oxide nanoparticles shows higher strength and faster endothelialization in animal models. These composites may allow thinner struts without sacrificing radial force.

Smart Degradation and Monitoring

Researchers are developing stents with embedded sensors or radiopaque markers that change signal as degradation progresses, allowing clinicians to monitor resorption non-invasively via MRI or X-ray. Such “smart stents” could inform patient-specific follow-up and early detection of complications.

Expanded Clinical Indications

Beyond coronary and peripheral arteries, biodegradable stents are being tested in non-vascular lumens such as the esophagus, urethra, and bile ducts. In these settings, the ability to dissolve prevents long-term complications like migration, hyperplasia, and stone formation. Pediatric applications remain a major driver, where temporary stenting can accommodate growth without surgical removal.

Conclusion: The Future of Vascular Tissue Engineering

Biodegradable stents embody the principles of vascular tissue engineering: they provide temporary mechanical support while guiding the body’s own repair processes, then disappear, leaving behind a fully functional, native vessel. While first-generation devices encountered setbacks, particularly with thrombosis, the lessons learned have informed a new wave of stents with thinner struts, optimized materials, and improved drug delivery. Clinical data from second-generation polymer and magnesium stents show competitive outcomes, and ongoing innovations in composite materials, patient-specific design, and smart degradation promise to further enhance safety and efficacy.

The road to widespread adoption will require robust clinical trials, manufacturing improvements, and careful patient selection. But the trajectory is clear: as populations age and cardiovascular disease remains the leading cause of death worldwide, the need for interventions that heal rather than permanently alter the vascular system will only grow. Biodegradable stents, as tissue engineering devices, offer a path toward that ideal. Their success will depend on continued collaboration between material scientists, engineers, clinicians, and regulators to turn this transformative concept into a routine clinical reality.

Key References and Further Reading: